Wolfe Research Upgrades CytomX Therapeutics (NASDAQ:CTMX) to “Strong-Buy”

Posted by Geri Gentry on May 20th, 2026

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) was upgraded by equities researchers at Wolfe Research to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Wedbush lifted their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Weiss Ratings lowered shares of CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research note on Thursday, March 19th. HC Wainwright dropped their price objective on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Jefferies Financial Group lifted their price objective on shares of CytomX Therapeutics from $8.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Finally, Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $10.00 to $12.00 and gave the company an “overweight” rating in a research note on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.10.

Check Out Our Latest Stock Report on CTMX

CytomX Therapeutics Trading Up 4.0%

CTMX stock opened at $3.64 on Tuesday. The company has a market cap of $619.49 million, a price-to-earnings ratio of -8.88 and a beta of 2.18. CytomX Therapeutics has a 12 month low of $1.72 and a 12 month high of $8.21. The firm has a 50-day moving average of $4.43 and a two-hundred day moving average of $4.55.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. The business had revenue of $10.26 million during the quarter, compared to analysts’ expectations of $4.68 million. As a group, equities analysts forecast that CytomX Therapeutics will post -0.45 earnings per share for the current year.

Insider Activity at CytomX Therapeutics

In related news, CFO Christopher Ogden sold 19,323 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $124,053.66. Following the completion of the sale, the chief financial officer directly owned 296,948 shares of the company’s stock, valued at approximately $1,906,406.16. This trade represents a 6.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Marcia Belvin sold 31,492 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $202,178.64. Following the sale, the senior vice president directly owned 300,760 shares of the company’s stock, valued at approximately $1,930,879.20. The trade was a 9.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 191,063 shares of company stock worth $1,226,624. Company insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE lifted its position in CytomX Therapeutics by 1,064.3% in the 1st quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company’s stock valued at $47,953,000 after purchasing an additional 9,326,480 shares during the last quarter. Janus Henderson Group PLC acquired a new position in CytomX Therapeutics during the 1st quarter valued at about $220,000. Ally Bridge Group NY LLC acquired a new position in CytomX Therapeutics during the 1st quarter valued at about $4,230,000. California State Teachers Retirement System acquired a new position in CytomX Therapeutics during the 1st quarter valued at about $415,000. Finally, Elmind Capital LP increased its stake in CytomX Therapeutics by 550.0% during the 1st quarter. Elmind Capital LP now owns 4,550,000 shares of the biotechnology company’s stock valued at $21,385,000 after buying an additional 3,850,000 shares during the period. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Company Profile

(Get Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.